Wonik Past Earnings Performance
Past criteria checks 0/6
Wonik's earnings have been declining at an average annual rate of -8.8%, while the Healthcare industry saw earnings growing at 11.6% annually. Revenues have been growing at an average rate of 10.3% per year.
Key information
-8.8%
Earnings growth rate
-8.7%
EPS growth rate
| Healthcare Industry Growth | 34.2% |
| Revenue growth rate | 10.3% |
| Return on equity | -1.8% |
| Net Margin | -3.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From Wonik Corporation's (KOSDAQ:032940) Revenues Yet
Nov 01
Is Wonik (KOSDAQ:032940) A Risky Investment?
Aug 12Wonik Corporation's (KOSDAQ:032940) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Jun 18Estimating The Fair Value Of Wonik Corporation (KOSDAQ:032940)
May 21I Ran A Stock Scan For Earnings Growth And Wonik (KOSDAQ:032940) Passed With Ease
May 03Reflecting on Wonik's (KOSDAQ:032940) Share Price Returns Over The Last Five Years
Feb 21Is Wonik (KOSDAQ:032940) A Risky Investment?
Jan 25Wonik Corporation (KOSDAQ:032940) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Dec 29Are Wonik's (KOSDAQ:032940) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 03
Revenue & Expenses Breakdown
How Wonik makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 138,819 | -4,927 | 56,658 | 1,285 |
| 30 Jun 24 | 137,116 | -7,556 | 53,601 | 1,221 |
| 31 Mar 24 | 132,341 | -9,337 | 51,572 | 1,182 |
| 31 Dec 23 | 129,877 | -2,970 | 48,728 | 1,210 |
| 30 Sep 23 | 126,785 | 21,617 | 47,094 | 1,169 |
| 30 Jun 23 | 121,338 | 28,231 | 45,331 | 1,125 |
| 31 Mar 23 | 114,991 | 36,035 | 42,813 | 1,117 |
| 31 Dec 22 | 108,089 | 38,242 | 40,324 | 1,064 |
| 30 Sep 22 | 103,238 | 22,595 | 39,320 | 919 |
| 30 Jun 22 | 97,617 | 19,598 | 36,872 | 972 |
| 31 Mar 22 | 94,358 | 24,858 | 33,531 | 849 |
| 31 Dec 21 | 94,675 | 28,488 | 32,708 | 726 |
| 30 Sep 21 | 90,396 | 121,603 | 31,114 | 671 |
| 30 Jun 21 | 91,787 | 112,407 | 30,677 | 462 |
| 31 Mar 21 | 91,060 | 120,585 | 29,569 | 398 |
| 31 Dec 20 | 87,494 | 79,391 | 30,242 | 355 |
| 30 Sep 20 | 91,501 | 1,424 | 32,786 | -27 |
| 30 Jun 20 | 90,880 | 8,069 | 35,155 | -15 |
| 31 Mar 20 | 90,669 | -24,193 | 38,099 | -9 |
| 31 Dec 19 | 90,386 | 36,563 | 39,436 | 0 |
| 30 Sep 19 | 88,331 | -64,905 | 40,648 | 243 |
| 30 Jun 19 | 86,999 | -66,368 | 40,154 | 182 |
| 31 Mar 19 | 82,848 | -48,438 | 38,662 | 93 |
| 31 Dec 18 | 80,295 | -69,664 | 36,648 | 0 |
| 30 Sep 18 | 79,894 | 18,426 | 36,517 | 0 |
| 30 Jun 18 | 76,251 | 19,025 | 33,488 | 0 |
| 31 Mar 18 | 70,638 | 18,011 | 29,779 | 0 |
| 31 Dec 17 | 67,244 | 13,787 | 27,606 | 0 |
| 30 Sep 17 | 60,466 | 7,125 | 21,398 | 0 |
| 30 Jun 17 | 60,936 | 76,804 | 21,190 | 0 |
| 31 Mar 17 | 62,986 | 72,178 | 20,736 | 0 |
| 31 Dec 16 | 64,804 | 70,649 | 20,770 | 0 |
| 30 Sep 16 | 80,201 | 72,050 | 23,151 | 0 |
| 30 Jun 16 | 73,943 | -67 | 22,270 | 0 |
| 31 Mar 16 | 60,012 | 209 | 18,518 | 0 |
| 31 Dec 15 | 59,528 | -875 | 17,124 | 0 |
| 31 Dec 14 | 56,839 | 239 | 11,666 | 0 |
| 30 Sep 14 | 58,668 | 9,827 | 11,123 | 0 |
| 30 Jun 14 | 59,141 | 7,329 | 10,702 | 0 |
| 31 Mar 14 | 58,577 | 7,347 | 10,550 | 0 |
| 31 Dec 13 | 57,257 | 4,569 | 10,981 | 0 |
Quality Earnings: A032940 is currently unprofitable.
Growing Profit Margin: A032940 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A032940 is unprofitable, and losses have increased over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare A032940's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A032940 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).
Return on Equity
High ROE: A032940 has a negative Return on Equity (-1.81%), as it is currently unprofitable.